You are here

Merck

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Fierce Pharma

Tue, 11/20/18 - 12:15 pm

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Mon, 11/19/18 - 11:29 am

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Merck starts rolling FDA submission for its Ebola vaccine, aiming to finish next year

Fierce Pharma

Thu, 11/15/18 - 09:45 am

Merck's Keytruda picks up first-in-class survival win in esophageal cancer

Fierce Pharma

Wed, 11/14/18 - 11:55 am

esophageal cancer

Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA

Endpoints

Tue, 11/13/18 - 09:55 am

GSK pancreatic cancer drug heads to phase 1 combo with Merck's Keytruda after positive mouse trial

Fierce Biotech

Mon, 11/12/18 - 11:47 pm

pancreatic cancer

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

CP Wire

Mon, 11/12/18 - 10:19 am

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

Mon, 11/12/18 - 09:54 am

Merck gets FDA okay for Keytruda as liver cancer therapy

Pharmaforum

Mon, 11/12/18 - 09:35 am

hepatocellular carcinoma

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

Endpoints

Tue, 11/6/18 - 11:52 pm

FDA Action Alert: EyePoint Pharma and Merck

BioSpace

Mon, 11/5/18 - 09:59 am

posterior segment uveitis

advanced hepatocellular carcinoma

Merck cuts back on vaccine commitment to West Africa as shipments to China ramp up

Stat

Thu, 11/1/18 - 11:15 pm

Merck's Keytruda secures broader lung cancer approval

Biopharma Dive

Wed, 10/31/18 - 11:57 am

squamous non-small cell lung cancer

'Unprecedented' demand for Merck's Gardasil drives monster Q3

Fierce Pharma

Tue, 10/30/18 - 07:00 pm

This Big Pharma Bet Isn't Paying Off Yet

Motley Fool

Sun, 10/28/18 - 07:42 pm

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer

Pharmaceutical Business Review

Fri, 10/26/18 - 09:52 am

clinical trials

Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag

Investors.com

Thu, 10/25/18 - 11:46 pm

Bristol-Myers Squibb

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

Fierce Pharma

Wed, 10/24/18 - 12:38 pm

PARP inhibitors

Clovis Oncology

ESMO: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer

Fierce Pharma

Mon, 10/22/18 - 12:15 pm

head and neck cancer

ESMO18: Merck’s STING agonist lacks bite on its own

Fierce Biotech

Mon, 10/22/18 - 10:45 am

Pages